Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670949 | 0.92 | ZDHHC7 (0.41) | CYP3A4ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL2671068 | 0.92 | DNM1 (0.45) | DNM1CA2CA1 | |
| SCHEMBL2670445 | 0.90 | DNM1 (0.48) | DNM1CA2CA1 | |
| SCHEMBL7339342 | 0.90 | ZDHHC7 (0.44) | DNM1TSHRFDPS | |
| SCHEMBL7337862 | 0.90 | ZDHHC7 (0.44) | DNM1TSHRFDPS | |
| SCHEMBL2671475 | 0.90 | DNM1 (0.36) | CYP3A4DNM1CA2CA1TSHR | |
| SCHEMBL338955 | 0.90 | CYP3A4 (0.39) | CYP3A4ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL2670779 | 0.87 | DNM1 (0.45) | DNM1CA2CA1FDPS | |
| SCHEMBL5961136 | 0.86 | ALOX5 (0.33) | CYP3A4ALDH1A1DNM1CA2CA1 | |
| SCHEMBL4299442 | 0.85 | DNM1 (0.48) | DNM1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| CN-110938339-A | Thermosetting release coating agent and laminated film | 日本化工涂料株式会社 | 2020-03-31 | — | — | CN | disclosed |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180265481-A1 | METHOD FOR PREPARATION OF CERTAIN 1,5 DISUBSTITUTED TETRAZOLES | LONZA LTD. (CH) | 2018-09-20 | — | — | US | disclosed |
| US-10065950-B2 | Substituted thiazoles as HIV integrase inhibitors | JAPAN TOBACCO INC. (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-2940019-B1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-3221305-B1 | METHOD FOR PREPARATION OF CERTAIN 1,5 DISUBSTITUTED TETRAZOLES | LONZA AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| EP-3221305-A1 | METHOD FOR PREPARATION OF CERTAIN 1,5 DISUBSTITUTED TETRAZOLES | Lonza Ltd (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375465-A9 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375479-A1 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | CCR1, CCL2, CCR5 | CYP3A4 1000/4885ADRB2 673/4885ADRB1 668/4885 |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | IMPA1, IMPDH1, TYMP | CYP3A4 181/4885ADRB2 2554/4885ADRB1 1637/4885 |
| US-10065950-B2 | Substituted thiazoles as HIV integrase inhibitors | TYMP, TYMS, IMPDH1 | CYP3A4 460/4885ADRB2 2576/4885ADRB1 1558/4885 |
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | IMPDH1, IMPDH2, SAV1 | CYP3A4 182/4885ADRB2 245/4885ADRB1 113/4885 |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, SAV1 | CYP3A4 182/4885ADRB2 245/4885ADRB1 113/4885 |
| US-20180265481-A1 | METHOD FOR PREPARATION OF CERTAIN 1,5 DISUBSTITUTED TETRAZOLES | TST, CYP3A5, SULT1A1 | CYP3A4 27/4885ADRB2 2935/4885ADRB1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.